DiscoveryProbe™ FDA-approved Drug Library: Atomic Benchmarks for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds approved by regulatory agencies including FDA, EMA, HMA, CFDA, and PMDA (see product page). Each compound is provided as a 10 mM DMSO solution, with stability for up to 24 months at –80°C. The library encompasses diverse mechanisms of action, including receptor modulation, enzyme inhibition, and signal pathway regulation. Its standardized, high-content format enables high-throughput drug screening and supports drug repositioning efforts across oncology, neurodegeneration, and other fields (Yang et al., 2025). Multiple peer-reviewed studies validate its use for target identification and translational workflows.

Biological Rationale

Drug discovery efforts increasingly rely on curated libraries of clinically validated compounds. The DiscoveryProbe™ FDA-approved Drug Library provides a systematic approach to identifying novel therapeutic targets and repositioning existing drugs. Each compound in the collection has undergone regulatory approval or is listed in recognized pharmacopeias, ensuring a high degree of bioactivity and clinical relevance. The inclusion of drugs with diverse mechanisms—such as doxorubicin (DNA intercalator), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor)—enables comprehensive interrogation of biological pathways and disease models. Libraries like DiscoveryProbe™ are especially valuable for addressing complex diseases like cancer and neurodegenerative disorders, where multifactorial mechanisms are involved. High-throughput and high-content screening (HTS/HCS) using such libraries facilitates rapid hypothesis testing, mechanistic validation, and the identification of lead candidates for translational research (related analysis).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library is intentionally designed for mechanistic diversity. It contains:

• Receptor agonists and antagonists (e.g., beta-blockers, opioid modulators)
• Enzyme inhibitors (e.g., kinase inhibitors, protease inhibitors)
• Ion channel modulators (e.g., calcium channel blockers, sodium channel antagonists)
• Signal pathway regulators (e.g., MAPK pathway inhibitors, AMPK activators)

Each compound is annotated with its primary mechanism, regulatory status, and known pharmacological targets. For example, mebendazole, included in the library, targets tubulin alpha 1A (TUBA1A) and can induce ZBP-1 mediated PANoptosis in acute myeloid leukemia cells (Yang et al., 2025). These mechanistic annotations enable researchers to select compounds for specific pathway interrogation or phenotypic screening.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds with regulatory approval or documented pharmacopeia listing (Product Documentation).
• All compounds are supplied as 10 mM DMSO solutions, stable for 12 months at –20°C and up to 24 months at –80°C, supporting reproducibility in HTS/HCS workflows (Product Docs).
• Mebendazole (library member) demonstrated anti-AML activity by inhibiting TUBA1A and promoting PANoptosis in vitro and in vivo AML models (Yang et al., 2025, DOI).
• The library has been successfully used for identification of novel Pif1 helicase inhibitors in oncology research (Lipo3K, 2023).
• Systematic screening with DiscoveryProbe™ has enabled rapid validation of translational hypotheses in signal pathway modulation and neurodegenerative disease models (MBP, 2024).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is used for:

• High-throughput screening (HTS) for drug repositioning and target identification
• High-content screening (HCS) in phenotypic assays
• Mechanistic studies in oncology, neurodegeneration, and infectious disease
• Benchmarking and validation of new assay platforms

For a detailed workflow perspective, see DiscoveryProbe™ FDA-approved Drug Library: Atomic Evidence, which this article extends by providing updated evidence and peer-reviewed clinical benchmarks.

Common Pitfalls or Misconceptions

• Pitfall: Assuming all compounds are suitable for in vivo use without additional toxicology validation. Clarification: Compounds are clinically approved but require dose optimization for new models.
• Pitfall: Believing the library covers all possible druggable targets. Clarification: Only approved or pharmacopeia-listed drugs are included; novel or investigational agents are not.
• Pitfall: Misinterpreting negative results as lack of pathway involvement. Clarification: Absence of effect may result from context-specific pharmacodynamics or cell line differences.
• Pitfall: Overlooking compound stability at suboptimal storage temperatures. Clarification: Adhere strictly to –20°C or –80°C storage for maximal stability.
• Pitfall: Equating regulatory approval with universal safety. Clarification: Approved drugs may have off-target effects or specific contraindications outside labeled indications.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is formatted for seamless integration into HTS and HCS pipelines. Compounds are supplied in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes for automated liquid handling. Pre-dissolved 10 mM DMSO stocks ensure uniform dosing and minimize solubility artifacts. Shipping options include blue ice for evaluation samples and room temperature for bulk orders, with re-cooling on arrival recommended. For screening, typical working concentrations range from 1–10 μM in cell-based assays, with DMSO kept below 0.5% (v/v) to avoid cytotoxicity. Data analysis workflows can leverage assay-annotated metadata and cross-reference compound identities with regulatory databases. For strategic discussion of translational integration, see From Mechanistic Insight to Precision Therapy, which this article clarifies by providing atomic-level workflow parameters and recent validation benchmarks.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library offers a gold-standard resource for high-throughput and high-content drug screening, fully annotated with regulatory and mechanistic metadata. Peer-reviewed evidence confirms its utility in pharmacological target identification, drug repositioning, and translational research. As disease models and screening technologies evolve, this library remains a foundational tool for rapid, reproducible, and mechanistically informed discovery. For further technical specifications and ordering information, visit the DiscoveryProbe™ FDA-approved Drug Library product page.